Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zealand Pharma AS's share price for the quarter that ended in Sep. 2024 was €107.5. Zealand Pharma AS's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 70.65 Mil. Therefore, Zealand Pharma AS's market cap for the quarter that ended in Sep. 2024 was €7,594.54 Mil.
Zealand Pharma AS's quarterly market cap
increased
from Mar. 2024 (€5,697.03 Mil) to Jun. 2024 (€8,404.30 Mil) but then
declined
from Jun. 2024 (€8,404.30 Mil) to Sep. 2024 (€7,594.54 Mil).
Zealand Pharma AS's annual market cap
increased
from Dec. 2021 (€818.51 Mil) to Dec. 2022 (€1,374.30 Mil) and
increased
from Dec. 2022 (€1,374.30 Mil) to Dec. 2023 (€2,948.09 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zealand Pharma AS's Enterprise Value for Today is €6,310.02 Mil.
Zealand Pharma AS Market Cap Historical Data
The historical data trend for Zealand Pharma AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zealand Pharma AS's Market Cap
For the Biotechnology subindustry, Zealand Pharma AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Market Cap falls into.
Zealand Pharma AS Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zealand Pharma AS's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (FRA:22Z) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zealand Pharma AS Market Cap Related Terms
Thank you for viewing the detailed overview of Zealand Pharma AS's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:22Z has been successfully added to your 